Vermillion Announces the Grant of Two Ovarian Cancer Diagnostic Patents

Monday, February 5, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

AUSTIN, Texas, Feb. 5, 2018 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML) announced today that it has been granted two

new US patents that significantly expand coverage for its core technologies, OVA1™ and Overa™.

  • The first, US Patent No. 9,816,995, entitled "Biomarker for ovarian cancer CTAP3-related proteins," describes and claims panels
    of biomarkers associated with ovarian cancer.
  • The second patent, US Patent No. 9,846,158, entitled "Predictive biomarkers for ovarian cancer," describes and claims sets of reagents used to measure biomarkers associated with ovarian cancer.

"These two new patents are significant wins for the organization and they further build upon our strong intellectual property position surrounding ovarian cancer and pelvic mass diagnostics," said Valerie Palmieri, President and CEO of Vermillion. "We are very excited about these new patents and the expanded coverage that they provide for tools for earlier detection, risk assessment, diagnosis and treatment planning for ovarian cancer"

About Vermillion

Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases.  The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.

Investor Relations Contact:Michael WoodLifeSci Advisors LLCTel 1-646-597-6983mwood@lifesciadvisors.com

 

Cision View original content:http://www.prnewswire.com/news-releases/vermillion-announces-the-grant-of-two-ovarian-cancer-diagnostic-patents-300592101.html

SOURCE Vermillion, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store